Search - tctmd.com

Displaying 41 - 60 of 190

Sort: Relevancy | Date

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presentation ESC 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presenter: Erwan Donal

August 31, 2024

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

News Daily News

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Yael L. Maxwell

July 22, 2024

Valvular Heart Disease Has a Diversity Problem

News Features

Valvular Heart Disease Has a Diversity Problem

Yael L. Maxwell

July 12, 2024

Dedicated Devices for Aortic Regurgitation Supported by Meta-analysis

News Conference News NY Valves 2024

Dedicated Devices for Aortic Regurgitation Supported by Meta-analysis

June 13, 2024

TEER May Be Option for Primary MR and ‘Red Zone’ Anatomy

News Conference News NY Valves 2024

TEER May Be Option for Primary MR and ‘Red Zone’ Anatomy

June 11, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

April 07, 2024

April 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

April 01, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

First-Ever Performance, Quality Metrics Created for Valvular and Structural Disease

News Daily News

First-Ever Performance, Quality Metrics Created for Valvular and Structural Disease

Michael O'Riordan

March 20, 2024

M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes

News Daily News

M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes

Michael O'Riordan

March 15, 2024

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

News Conference News TCT 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

October 26, 2023

Medical Therapy ‘Disappointing’ Prior to TEER for Functional MR: TVT Registry

News Daily News

Medical Therapy ‘Disappointing’ Prior to TEER for Functional MR: TVT Registry

Michael O'Riordan

September 27, 2023

Balloon-Expandable Redo TAVI Shows Promise in Real-world Cohort

News Daily News

Balloon-Expandable Redo TAVI Shows Promise in Real-world Cohort

Yael L. Maxwell

September 06, 2023

US and European Valvular Guidelines Mostly Concordant, Analysis Finds

News Daily News

US and European Valvular Guidelines Mostly Concordant, Analysis Finds

August 21, 2023

Pacemaker Implantation Still Risky, Not Rare With Self-Expanding TAVI Devices

News Daily News

Pacemaker Implantation Still Risky, Not Rare With Self-Expanding TAVI Devices

July 21, 2023

Solid Anchoring, Good Echo Results With Transapical TMVR at 2 Years

News Conference News TVT 2023

Solid Anchoring, Good Echo Results With Transapical TMVR at 2 Years

Michael O'Riordan

June 09, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.